From ARRD I believe.
She mentioned a Rapamycin clinical trial as well.
In this video, Professor Andrea Maier from National University of Singapore presents about the ongoing clinical trials aimed at optimizing human health and potentially reversing the aging process. Join us as we explore groundbreaking interventions on:
• SGLT2 Inhibitors: Can these heart medications improve outcomes in healthy individuals, not just those with diabetes?
• Alpha-Ketoglutarate: A promising supplement being tested for its potential to enhance recovery and healthspan.
• Nicotinamide Mononucleotide (NMN): How this supplement could improve functional outcomes and quality of life in middle-aged individuals.
• Multivitamins and Minerals: Are they beneficial or harmful? We break down the latest research and ongoing trials.
2 Likes
AnUser
#2
What we need to know:
(1) What is the primary and secondary endpoints of the trials?
(2) Do they have adequate amount of participants, enough to detect the effect they expect?
Without this information, it’s gossip and feel good study information, which is okay
Don’t forget rapamycin. I spoke with her in December at the Longevity Summit and the rapamycin trial should be starting this month and completed in 6 months… so things are (finally) progressing for her group at NUS.
1 Like
AnUser
#4
Is it actually a trial with a good endpoint and with adequate amount of participants, or is it just another exploratory study looking for side effects?
1 Like
